

Supplementary table S2

Selected clinical trials showing association of MMF with diseases suggested to be associated with MMF molecular footprint by synlet enrichment between or within pathways. Only the drug association determined by synlet associated pathways is indicated, even if multiple drugs are used in a trial (as is often the case). Importantly, few trials were designed to differentiate MMF use from other drug combinations, yet apply MMF as part of basic treatment or within a list of potential treatment options.

Indication	Paired Drug	Trial	Phase	Aim	Status	Outcome
Atherosclerosis in SLE patients	-	NCT01101802	IV	MMF Efficacy	Completed	Not specified
Lupus Nephritis	-	NCT00377637	III	Superiority to Azathioprine (standard of care)	Completed	Superior
SLE with extra-renal Manifestation	-	NCT01112215	IV	Superiority to Azathioprine (standard of care)	Recruiting	-
Multiple Sclerosis	Interferon-beta-1a	NCT00618527	0	Prolonging the efficacy of interferon	Ongoing	-
		NCT00324506	II	Safety and tolerability	Unknown	-
		NCT00223301	II/III	Improvement of patient condition	Completed	Unknown
Anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis	Infliximab	NCT00753103	II	Superiority of Infliximab over standard immunosuppression alone	Completed	Unknown
Blood stem-cell transplantation in Chronic Myelogenous Leukemia	Interferon-alpha	NCT00110058	II	Fludarabine together with radiation + immunosuppression	Completed	Unknown
Lymphoblastic Leukemia and Chronic Myelogenous Leukemia	Dasatinib, Nilotinib	NCT00036738	II	Better tradeoff between graft vs. tumor and graft vs. host	Recruiting	-

Kidney Transplantation	Efalizumab	NCT00729768	II/III	Efalizumab versus Cyclosporine (in both cases MMF)	Withdrawn prior to enrollment	-
Kidney Transplantation	Efalizumab	NCT00472082	I/II	Replacement of Tacrolimus by Efalizumab	Terminated (request of the drug manufacturer)	-
Lupus Nephritis	Etanercept	NCT00447265	II	Improvement of addition to standard care (including MMF) over standard care alone	Terminated	-
Autoimmune diseases like arthritis	Efalizumab	NCT00777400	I/II	Superiority of Efalizumab + Sirolimus vs. Tacrolimus + MMF (Treg maximization)	Terminated (safety & trial feasibility)	-
Graft Versus Host Disease	Etanercept	NCT00639717	II	More effective prophylaxis	Recruiting	-
Type 1 Diabetes	Anakinra	NCT01346085	I/II	Calcineurin Inhibitor (CNI)-Free Immunosuppression	Ongoing	-